Business Context and Reporting Period
This Form 8-K Current Report was filed by MediciNova, Inc. on September 26, 2013, covering events occurring on September 21, 2013. The filing addresses the departure of a senior executive and the execution of a related severance agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific severance package for the departing officer:
- Severance Payment: $97,850 (gross).
- COBRA Health Insurance: $11,540.44 (six months of premiums).
- Consulting Fee: $3,000 per month for up to one year.
Material Changes
The primary material change reported is the termination of employment for Kirk Johnson, Ph.D., the Company's Chief Scientific Officer, effective September 21, 2013. This event supersedes his previous Executive Employment Agreement and Severance Protection Agreement.
Outlook, Risks, and Unusual Items
Management Commentary and Arrangements:
- Dr. Johnson will transition to a consulting role for up to ten hours per month for one year.
- He has agreed to a non-compete and non-solicitation clause during the consulting term.
- He has provided a general release and waiver of claims against the Company.
- The severance payment is contingent upon the expiration of the applicable revocation period.
- The filing notes that the summary of the agreement is qualified by the full text of the agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact terms of the non-compete and non-solicitation clauses in Exhibit 10.1.
- Confirm the status of the revocation period to determine the timing of the severance payout.
- Assess the impact of the Chief Scientific Officer's departure on the Company's ongoing research and development pipeline.
- Review the consulting agreement to ensure the scope of work aligns with the Company's strategic needs.